Market Intelligence, Clinical Progress, and High-Purity Reagents for Endosomal Recycling, Exosome Secretion, and Oncology/Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RAB11A/B drug discovery. The resolved target is RAB11A (UniProt P62491), but the toolkit covers both RAB11A and RAB11B isoforms, along with key effectors and related trafficking nodes.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Wild-type Antigen | RAB11A/B Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. GTP-binding verified. | View RAB11A Products |
| Conformation Mutants | RAB11A Q70L (GTP-locked) / S25N (GDP-locked). Definitive activity state controls for pulldown & activity assays. | View RAB11A Products |
| Isoform B Panel | RAB11B Wild-type & Mutant Proteins. Isoform-specific reagents for differentiated oncology targets. | View RAB11B Products |
| Gene Delivery | RAB11A/B Promise-ORF / Lentivirus. Full-length ORF with native prenylation motif for stable trafficking reporter cell lines (fluorescent tags available). | View RAB11A Products |
| Benchmark Ab | Anti-RAB11A/B Reference Antibody. Recombinant rabbit monoclonal for Western, IHC, ICC validation. | View RAB11A Products |
| Validator | RAB11A/B siRNA Set (3 unique sequences). For knockdown verification and specificity control in recycling assays. | View RAB11A Products |
| Effector Protein | FIP2 (RAB11-FIP2) Recombinant Protein. Critical effector for pulldown interaction assays and PPI screening. | View FIP2 Products |
| Related Target | RAB25. Oncogenic endosomal RAB; synergistic recycling pathway with RAB11 in solid tumors; compensatory mechanism studies. | View RAB25 Products |
| Related Target | EGFR. Major recycling cargo dependent on RAB11 function for sustained signaling. | View EGFR Products |
| Related Target | RAB5A. Early endosome partner; crucial for endosomal pathway specificity screening (counter-screen). | View RAB5A Products |
| Related Target | RAB11FIP1 (RCP). Key effector linking RAB11 to motor proteins; critical PPI node for targeted inhibition. | View RAB11FIP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTP/GDP Conformation Discrimination | Activity-locked Mutants (Q70L GTP-locked, S25N GDP-locked) with >95% purity for definitive pulldown controls; batch-verified by mass spec. |
| Isoform Selectivity Screening (A vs B) | Strictly purified RAB11A vs RAB11B proteins with <0.1% cross-contamination verified by mass spec and sequencing. |
| Membrane Recruitment & Trafficking Validation | Lentiviral ORF particles with mCherry/GFP tags; HEK293T expressed for native folding and prenylation. |
| Effector Binding Validation | Matched FIP2/RCP effector proteins available for co-crystal, SPR, and BLI studies. |
| Family-Wide Selectivity Screening | Ortholog panel: RAB11A, RAB11B, RAB25, RAB5A proteins. Sequence Verified, >95% purity, endotoxin controlled. |
Live RAB11A/B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RAB11A/B represents a paradigm shift from surface receptor inhibition to intracellular trafficking modulation. Traditionally considered undruggable small GTPases, recent advances in allosteric modulators, peptide inhibitors, and targeted protein degradation (PROTACs) are opening new avenues. The race is intensifying in both oncology—where receptor recycling drives targeted therapy resistance and metastasis—and virology, where RAB11 mediates viral particle egress (SARS-CoV-2, Influenza, HIV). Current R&D is pivoting from genetic knockout models toward pharmacological inhibition using covalent modifiers, allosteric peptides, and modalities that disrupt RAB11-effector protein-protein interactions. No compounds have yet reached Phase II, but the preclinical pipeline is expanding rapidly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Emerging biotechs, academic consortia | Solid tumors, metastatic cancers | GTPase Activity Assay (Need WT + Mutant panels for mechanism validation) |
| Peptide / Miniprotein Inhibitors (PPI) | MD Anderson, Scripps, Peptide platforms | Viral infections (SARS-CoV-2, HIV), neurodegenerative diseases | Pulldown & SPR/BLI effector competition (Need GTP-locked RAB11A + effector proteins) |
| PROTAC / Degrader | Arvinas-type platforms (preclinical) | Drug-resistant tumors | Cellular degradation assays (Need high-expression lentivirus for stable cell lines) |
| siRNA / RNAi | Silence Therapeutics, Alnylam (exploratory) | Pancreatic cancer, antiviral | Knockdown validation (Need sequence-verified siRNA sets + cell-based trafficking assays) |
Key Molecular Differentiation & Assay Strategy
Distinctive Factors
- Conformational Specificity: RAB11 activity depends on GTP/GDP state. Inhibitors may stabilize GDP (inactive) or block GTP binding. Accurate assay controls require GTP-locked (Q70L) and GDP-locked (S25N) mutants with >95% purity and endotoxin <1 EU/µg. TarMart provides preloaded mutant panels with off-rate verification.
- Isoform Selectivity: RAB11A and RAB11B share ~85% sequence identity but differ in tissue distribution and cancer dependency (e.g., RAB11B is upregulated in pancreatic cancer). Cross-screening against RAB25 is essential to avoid off-target effects. TarMart offers a triple panel (A/B/25) with mass spec certification.
- Effector Interface Disruption: Blocking RAB11-FIP interactions (e.g., FIP2, RCP) can reduce toxicity versus complete RAB11 inhibition. Assays require full-length, active effector proteins for pulldown/SPR. TarMart supplies RAB11-effector complex co-purification and biotinylated RAB11 for HTS.
- Subcellular Localization: Validating inhibition of perinuclear recycling endosomes (vs. early/late endosomes) demands live-cell imaging with fluorescent RAB11. TarMart offers pre-made lentiviral particles (RAB11A-mCherry, RAB11B-GFP) with >90% transduction efficiency.
Recommended Screening Cascade
- Primary (biochemical): GTPase activity inhibition (Malachite Green) with WT RAB11A; competitive binding using GTP-locked mutant for allosteric hits.
- Secondary (cell-based): Transferrin receptor recycling flow cytometry; migration/invasion assay (Boyden Chamber) for anti-metastatic phenotype.
- Counter-screen (safety): RAB5/RAB7 activity cross-screen (using TarMart proteins); cytotoxicity controls via RAB11A/B siRNA parallel validation.
Conclusion & TarMart Product Strategy
By offering conformation-specific mutants, isoform-specific proteins, matched effectors, and lentiviral delivery systems, TarMart positions itself as the standard-setting supplier for the emerging "GTPase inhibitor" drug discovery field. The recommended core product bundles include:
- Mechanism Set: WT RAB11A + Q70L + S25N triple pack
- Isoform Discriminator: RAB11A vs RAB11B protein pair
- Pathway Complete: RAB11A + FIP2 + MYO5B motor protein triad
Cross-selling with RAB25, EGFR, RAB5A, and FIP1 will satisfy customers’ need for endosomal pathway validation and resistance mechanism studies.
All product links and technical specifications are based on TarMart’s verified offerings. For inquiries, contact TarMart support.